Medical Properties Trust, Inc. MPT
3.57
(0.03)
(0.83%)
as of 25 Sep
- Market cap
- $2.1B
- P/E
- 0.0×
Follow MPT
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
2.71 | 2.77 | 3.09 | 3.26 | |
P/FCF ratio |
10.68 | 10.30 | 11.07 | 11.73 | |
P/Operating CF |
44.24 | (194.08) | 18.77 | 164.11 | |
P/B ratio |
0.61 | 0.61 | 0.65 | 0.65 | |
Price to Tangible BV |
0.61 | 0.61 | 0.65 | 0.65 | |
EV/Sales |
11.84 | 12.00 | 12.51 | 13.14 | |
EV/EBITDA |
33.81 | 34.30 | 37.02 | 39.10 | |
EV/Operating CF |
53.22 | 55.55 | 52.70 | 83.23 | |
EV/FCF |
46.65 | 44.68 | 44.82 | 47.22 | |
Quick Ratio |
3.12 | 3.11 | 2.63 | 2.68 | |
Current Ratio |
3.12 | 3.11 | 2.63 | 2.68 | |
Net Debt/EBITDA |
104.84 | 105.93 | 80.86 | 136.09 | |
Debt/Assets |
65.81% | 65.45% | 64.64% | 64.43% | |
Debt/Equity |
2.16 | 2.13 | 2.10 | 2.06 | |
Asset Turnover |
0.07 | 0.07 | 0.07 | 0.06 | |
Operating CF/Net income |
(24.06) | (0.43) | 9.25 | (0.24) | |
Capex/Depreciation |
(0.09) | 0.07 | 0.06 | 0.38 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
13.41% | 12.78% | 9.09% | 15.89% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
1.87% | 0.23% | (1.89%) | 5.20% | |
Graham Net Nets |
(3.22) | (3.21) | (2.98) | (2.95) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(1.16%) | (4.54%) | (9.20%) | (23.27%) | |
Free Cash Flow Yield |
9.37% | 9.71% | 9.03% | 8.52% | |
Revenue per Share |
0.43 | 0.42 | 0.45 | 0.40 | |
Operating CF per Share |
0.10 | (0.02) | 0.27 | 0.03 | |
Capex per Share |
(0.01) | 0.01 | 0.01 | 0.05 | |
Free Cash Flow per Share |
0.09 | (0.01) | 0.27 | 0.08 | |
Cash per Share |
0.66 | 0.71 | 0.90 | 0.66 | |
Shareholders Equity per Share |
7.53 | 7.61 | 7.67 | 7.75 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
7.53 | 7.61 | 7.67 | 7.75 | |
Free Cash Flow |
55.37 | (8.48) | 164.40 | 47.49 | |
Working Capital |
912.33 | 913.89 | 892.42 | 797.53 | |
Capital Expenditures |
(7.07) | 5.78 | 4.33 | 28.92 | |
Net Current Asset Value |
(8,905.43) | (8,869.86) | (8,953.01) | (8,989.36) | |
EV/EBIT |
277.32 | 287.16 | 413.47 | 616.05 | |
Capex to Sales |
0.03 | (0.02) | (0.02) | (0.12) | |
Net Profit Margin |
(1.00%) | 13.02% | 6.40% | (32.73%) | |
Price to Operating Income |
63.47 | 66.20 | 102.15 | 153.05 | |
| Other line items | |||||
Average Receivables |
900.17 | 852.17 | 818.89 | 798.89 | |
Average Payables |
462.43 | 442.22 | 501.66 | 447.14 | |
Average Assets |
14,949.09 | 14,808.28 | 14,648.19 | 15,080.18 | |
Average Common Equity |
4,666.86 | 4,653.92 | 4,720.52 | 5,051.23 |
Columns are period end dates